Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Laura M. Geffert"'
Autor:
Jong K. Yun, Taryn E. Dick, Robert F. Paulson, Su Fern Tan, Hong Gang Wang, David F. Claxton, Shantu Amin, Mark Kester, Arati Sharma, Laura M. Geffert, Dhimant Desai, Thomas P. Loughran, Arun Sharma, Kenichiro Doi, Todd E. Fox, Shailaja Hegde, Jeremy A. Hengst
Publikováno v:
Cancer Translational Medicine, Vol 3, Iss 4, Pp 109-121 (2017)
Aim: To further characterize the selectivity, mechanism of action, and therapeutic efficacy of the novel small molecule inhibitor, SKI-178. Methods: We used the state-of-the-art cellular thermal shift assay technique to detect “direct target engage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::750fe81c44c76bd9c931d98300a21786
http://www.cancertm.com/article.asp?issn=2395-3977
http://www.cancertm.com/article.asp?issn=2395-3977
Autor:
Cienna L. Nielsen, Christopher K. Surratt, Nicholas E. Wolters, Gianluigi Tanda, Maddalena Mereu, Rehana K. Leak, Martín Indarte, Jessica E. Jorvig, Elizabeth Dallman, Laura M. Geffert, Mary Ellen Amos, Hailey Choi, Caitlin A. Munro, Ruben I. Goldstein, Jonathan L. Katz, Jeffry D. Madura, Jeffery N. Talbot
Publikováno v:
Pharmacol Biochem Behav
Rational design of lead compounds targeting monoamine transporters (MATs) is critical to developing novel therapeutics to treat psychiatric disorders including depression and substance abuse. A 3-D dopamine transporter (DAT) computer model was used t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91740c0c191642d61b94a46a13ee6f7
https://doi.org/10.1016/j.pbb.2016.08.007
https://doi.org/10.1016/j.pbb.2016.08.007
Publikováno v:
Expert Opinion on Drug Discovery. 8:1399-1414
In spite of research efforts spanning six decades, the most prominent antidepressant drugs to date still carry several adverse effects, often serious enough to warrant discontinuation of the drug. Molecular mechanisms of depression are now better und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a94e1e847aeadaddc3242823cbe660
https://doi.org/10.1517/17460441.2013.830102
https://doi.org/10.1517/17460441.2013.830102
Autor:
Phillip N. Taylor, Tammy L. Nolan, David J. Lapinsky, Yi Liu, Jeffry D. Madura, Mary Ellen Amos, Jeffery N. Talbot, Christopher K. Surratt, Laura M. Geffert, Martín Indarte, Sankar Manepalli
Publikováno v:
ACS Chemical Neuroscience. 2:544-552
Ligand virtual screening (VS) using the vestibular binding pocket of a 3-D monoamine transporter (MAT) computational model followed by in vitro pharmacology led to the identification of a human serotonin transporter (hSERT) inhibitor with modest affi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab52a6d6da13d77ef6d9affb7611222
https://doi.org/10.1021/cn200044x
https://doi.org/10.1021/cn200044x
Autor:
Laura M. Geffert, Benedict J. Kolber, Jeffry D. Madura, Christopher K. Surratt, Tammy L. Nolan
Publikováno v:
ACS Chemical Neuroscience
Discovery of new inhibitors of the plasmalemmal monoamine transporters (MATs) continues to provide pharmacotherapeutic options for depression, addiction, attention deficit disorders, psychosis, narcolepsy, and Parkinson’s disease. The windfall of h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b492906093d91d9bbd24393110d29060
https://pubmed.ncbi.nlm.nih.gov/25003748
https://pubmed.ncbi.nlm.nih.gov/25003748
Autor:
Mary Ellen Amos, Nicholas E. Wolters, Christopher K. Surratt, Caitlin A. Munro, Gianluigi Tanda, Jeffery N. Talbot, Martín Indarte, Jessica Larkey, Elizabeth Dallman, Laura M. Geffert, Erica Tolle, Jonathan L. Katz, Jeffry D. Madura
Publikováno v:
The FASEB Journal. 28
A continuing challenge in treating depression is therapeutic delay and resistance to available treatments. Hence, the growing interest in developing antidepressants (AD) with rapid onset (hours to days) and novel mechanisms of action. For example, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0aa4706baa54d99d6f535bc601e8c7
https://doi.org/10.1096/fasebj.28.1_supplement.1144.1
https://doi.org/10.1096/fasebj.28.1_supplement.1144.1
Autor:
Jeremy A. Hengst, Hong Gang Wang, Laura M. Geffert, Taryn E. Dick, David F. Claxton, Robert F. Paulson, Mark Kester, Jong K. Yun, Thomas P. Loughran
Publikováno v:
Cancer Research. 76:323-323
Acute myeloid leukemia (AML) is a heterogeneous and rapidly progressing blood cell cancer caused by numerous cytogenetic alterations. Although significant improvement in treatment of AML has been made, the unfortunate reality is that currently availa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86244cde1d782dec701bff0f1837836a
https://doi.org/10.1158/1538-7445.am2016-323
https://doi.org/10.1158/1538-7445.am2016-323